Close Menu

NEW YORK, Oct 16 - DoubleTwist, next in the bioinformatics IPO queue, is seeking to raise at least $65 million through an offer of 5 million shares in a proposed price range of $13 to $15 a share, according to an S-1 amendment the company filed Friday.

The company, which originally announced its plan to go public on Sept. 1, has applied to be listed on the Nasdaq under the symbol DBLT. A DoubleTwist spokeswoman said that the date the company's stock would begin trading has not yet been determined.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new approach may help limit the number of fish that are mislabeled at markets or restaurants, according to New Scientist.

Nature News reports that researchers in Japan hope to soon test the use of reprogrammed stem cells to treat damaged corneas.

At Slate, the R Street Institute's Nila Bala discusses the privacy rights of suspects that genetic genealogy approaches in law enforcement bring up.

In PNAS this week: numerous mobile genetic elements contribute to Vibrio cholerae drug resistance, troponin I mutations in sudden infant deaths, and more.